Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Implementation of Genetic Screening to Prevent Severe Cutaneous Adverse Drug Reactions Is Crucial—Rebuttal From the Devil’s Antagonist—Reply

Implementation of Genetic Screening to Prevent Severe Cutaneous Adverse Drug Reactions Is... Letters treatments. In contrast to systemic symptoms, this subset of pa- reactions (SCARs). In the last 2 decades, endeavors by inter- tients with dermatomyositis is characterized by milder inflam- national multidisciplinary scientific networks have greatly ad- matory cutaneous manifestations, usually associated with cal- vanced our understanding of the pathogenesis of SCARs. An cinosis cutis and peripheral edema. Skin disease remission is important innovation has been translating the discoveries in easier to achieve in these patients compared with those who SCAR pharmacogenetics into preventive genetic screening of have long-standing systemic symptoms. at-risk populations. Notable HLA antigen drug associations for In this observation, we describe a rare case of dermatomyo- SCARs include HLA-B*57:01 (abacavir-induced Stevens- sitis with Degos-like skin lesions. To our knowledge, the Johnson syndrome/toxic epidermal necrolysis [SJS/TEN] and literature contains few other reports of analogous cutaneous drug reaction eosinophilia and systemic symptoms [DRESS]), manifestations in connective tissue diseases, including derma- HLA-B*15:02 (carbamazepine-induced SJS/TEN), HLA- tomyositis, systemic lupus erythematosus, and systemic B*58:01 (allopurinol-induced SJS/TEN and DRESS), and HLA- 3,4 sclerosis. This case report describes a specific manifestation B*13:01 (dapsone-induced DRESS). Screening programs have been established by governments across Asia, including of dermatomyositis and a phenotypic overlap: both a Degos disease–like http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Dermatology American Medical Association

Implementation of Genetic Screening to Prevent Severe Cutaneous Adverse Drug Reactions Is Crucial—Rebuttal From the Devil’s Antagonist—Reply

Divito, Sherrie J.
JAMA Dermatology , Volume 156 (2) – Feb 18, 2020
Download PDF
3 pages

Loading next page...
 
/lp/american-medical-association/implementation-of-genetic-screening-to-prevent-severe-cutaneous-vcsZBeh5ss

References (3)

Publisher
American Medical Association
Copyright
Copyright 2019 American Medical Association. All Rights Reserved.
ISSN
2168-6068
eISSN
2168-6084
DOI
10.1001/jamadermatol.2019.3335
Publisher site
See Article on Publisher Site

Abstract

Letters treatments. In contrast to systemic symptoms, this subset of pa- reactions (SCARs). In the last 2 decades, endeavors by inter- tients with dermatomyositis is characterized by milder inflam- national multidisciplinary scientific networks have greatly ad- matory cutaneous manifestations, usually associated with cal- vanced our understanding of the pathogenesis of SCARs. An cinosis cutis and peripheral edema. Skin disease remission is important innovation has been translating the discoveries in easier to achieve in these patients compared with those who SCAR pharmacogenetics into preventive genetic screening of have long-standing systemic symptoms. at-risk populations. Notable HLA antigen drug associations for In this observation, we describe a rare case of dermatomyo- SCARs include HLA-B*57:01 (abacavir-induced Stevens- sitis with Degos-like skin lesions. To our knowledge, the Johnson syndrome/toxic epidermal necrolysis [SJS/TEN] and literature contains few other reports of analogous cutaneous drug reaction eosinophilia and systemic symptoms [DRESS]), manifestations in connective tissue diseases, including derma- HLA-B*15:02 (carbamazepine-induced SJS/TEN), HLA- tomyositis, systemic lupus erythematosus, and systemic B*58:01 (allopurinol-induced SJS/TEN and DRESS), and HLA- 3,4 sclerosis. This case report describes a specific manifestation B*13:01 (dapsone-induced DRESS). Screening programs have been established by governments across Asia, including of dermatomyositis and a phenotypic overlap: both a Degos disease–like

Journal

JAMA Dermatology – American Medical Association

Published: Feb 18, 2020

There are no references for this article.